Popular drugs for common male health problems can affect their sexual health

Mar 07, 2011

A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.

Researchers led by Abdulmaged M. Traish, MBA, PhD, of Boston University School of Medicine, examined data reported in various clinical studies from the available literature concerning the side effects of the 5 alpha reductase , finasteride and dutasteride.

Prolonged adverse side effects on sexual function, such as ED, depression and diminished libido, were reported by a subset of men. Drug-related reduction in libido occurred in 4.2% and 1.8% of patients in the dutasteride and placebo groups, respectively. Reduced ejaculation and semen volume were also reported and in some patients, these drugs were associated with depression.

"For these reasons, patients and doctors are urged to discuss these issues openly and candidly and assess the risk benefit ratio prior to commencing therapy with 5a-reductase inhibitors" Dr. Traish notes.

Dr. Irwin Goldstein, editor-in-chief of The Journal of , has seen and evaluated numerous such patients. He further explained the importance of this study. "Young men are being prescribed 5 alpha reductase inhibitors as hair loss treatments that may negatively impact their sexual life, possibly for a prolonged time after stopping the medication. Older men with symptoms of lower urinary tract symptoms or fearful of , now have to deal with new onset sexual and . The growing use of 5 alpha reductase inhibitors is causing concerns." Clearly more research is needed to better understand the basis for these drug-associated but it is evident that 5 alpha reductase inhibitors prevent the synthesis of very critical central nervous system neurosteroids and lower a very important sex steroid hormone, dihydrotestosterone.

Explore further: Added benefit of vedolizumab is not proven

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

11 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0